161 related articles for article (PubMed ID: 27282551)
1. Combined low-dose antimuscarinics for refractory detrusor overactivity in children.
Fahmy A; Youssif M; Rhashad H; Mokhless I; Mahfouz W
J Pediatr Urol; 2016 Aug; 12(4):219.e1-5. PubMed ID: 27282551
[TBL] [Abstract][Full Text] [Related]
2. Combined antimuscarinics for treatment of neurogenic overactive bladder.
Nardulli R; Losavio E; Ranieri M; Fiore P; Megna G; Bellomo RG; Cristella G; Megna M
Int J Immunopathol Pharmacol; 2012; 25(1 Suppl):35S-41S. PubMed ID: 22652160
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of combined low- and standard-dose trospium and solifenacin for moderate overactive bladder symptoms in elderly men and women.
Kosilov KV; Loparev SA; Ivanovskaya MA; Kosilova LV
Urol Int; 2014; 93(4):470-3. PubMed ID: 25170796
[TBL] [Abstract][Full Text] [Related]
4. Dose escalation improves therapeutic outcome: post hoc analysis of data from a 12-week, multicentre, double-blind, parallel-group trial of trospium chloride in patients with urinary urge incontinence.
Bödeker RH; Madersbacher H; Neumeister C; Zellner M
BMC Urol; 2010 Sep; 10():15. PubMed ID: 20840754
[TBL] [Abstract][Full Text] [Related]
5. Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials.
Staskin DR; Rosenberg MT; Sand PK; Zinner NR; Dmochowski RR
Int J Clin Pract; 2009 Dec; 63(12):1715-23. PubMed ID: 19930332
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Adherence of Flexibly Adding on a Second Antimuscarinic Agent for Patients with Refractory Overactive Bladder.
Wang CC; Jiang YH; Kuo HC
Low Urin Tract Symptoms; 2017 Jan; 9(1):27-32. PubMed ID: 28120445
[TBL] [Abstract][Full Text] [Related]
7. Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects.
Amend B; Hennenlotter J; Schäfer T; Horstmann M; Stenzl A; Sievert KD
Eur Urol; 2008 May; 53(5):1021-8. PubMed ID: 18243516
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the efficacy and tolerability of solifenacin succinate with or without previous use of trospium chloride.
Metello J; Nogueira B; Torgal M; Colaço J; Vieira A; Gonçalves V; Retto H
Int Urogynecol J Pelvic Floor Dysfunct; 2007 Sep; 18(9):1021-5. PubMed ID: 17211528
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of Solifenacin and Trospium for Managing of Severe Symptoms of Overactive Bladder in Patients With Benign Prostatic Hyperplasia.
Kosilov KV; Loparev SA; Ivanovskaya MA; Kosilova LV
Am J Mens Health; 2016 Mar; 10(2):157-63. PubMed ID: 26186951
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of overactive bladder in older women increased doses of antimuscarinic drugs safe and effective alternative to existing methods].
Kosilov KV; Loparev SA; Krasnykh MA; Kosilova LV
Adv Gerontol; 2014; 27(1):149-55. PubMed ID: 25051773
[TBL] [Abstract][Full Text] [Related]
11. Study of the population pharmacokinetic characteristics of once-daily trospium chloride 60 mg extended-release capsules in patients with overactive bladder and in healthy subjects.
Harnett MD; Shipley J; MacLean L; Schwiderski U; Sandage BW
Clin Drug Investig; 2013 Feb; 33(2):133-41. PubMed ID: 23203138
[TBL] [Abstract][Full Text] [Related]
12. Which antimuscarinic agents used in the treatment of overactive bladder increase heart rate? a prospective randomized clinical trial.
Cetinel B; Onal B; Gultekin MH; Guzelsoy M; Turegun FA; Dincer M
Int Urol Nephrol; 2019 Mar; 51(3):417-424. PubMed ID: 30725387
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: with special reference to age-dependent parameters.
Humblet M; Verpoorten C; Christiaens MH; Hirche H; Jansen K; Buyse G; van Gool JD
Neurourol Urodyn; 2015 Apr; 34(4):336-42. PubMed ID: 24436114
[TBL] [Abstract][Full Text] [Related]
14. [Intravesical treatment of overactive bladder syndrome].
Haferkamp A; Hohenfellner M
Urologe A; 2006 Oct; 45(10):1283-8. PubMed ID: 16972089
[TBL] [Abstract][Full Text] [Related]
15. Trospium chloride: the European experience.
Madersbacher H; Rovner E
Expert Opin Pharmacother; 2006 Jul; 7(10):1373-80. PubMed ID: 16805722
[TBL] [Abstract][Full Text] [Related]
16. New once-daily formulation for trospium in overactive bladder.
Chapple C
Int J Clin Pract; 2010 Oct; 64(11):1535-1540. PubMed ID: 20846201
[TBL] [Abstract][Full Text] [Related]
17. Trospium chloride in patients with neurogenic detrusor overactivity: is dose titration of benefit to the patients?
Menarini M; Del Popolo G; Di Benedetto P; Haselmann J; Bödeker RH; Schwantes U; Madersbacher H;
Int J Clin Pharmacol Ther; 2006 Dec; 44(12):623-32. PubMed ID: 17190372
[TBL] [Abstract][Full Text] [Related]
18. [High doses of trospium chloride in patients with idiopathic overactive bladder. Data of large-scale, multicenter observational program Resource].
Krivoborodov GG; Tur EI; Efremov NS; Shkolnikov ME
Urologiia; 2016 Aug; (4):29-34. PubMed ID: 28247723
[TBL] [Abstract][Full Text] [Related]
19. Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms.
Zinner NR; Dmochowski RR; Staskin DR; Siami PF; Sand PK; Oefelein MG
Neurourol Urodyn; 2011 Sep; 30(7):1214-9. PubMed ID: 21462240
[TBL] [Abstract][Full Text] [Related]
20. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience.
Wagg A; Compion G; Fahey A; Siddiqui E
BJU Int; 2012 Dec; 110(11):1767-74. PubMed ID: 22409769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
